Dong-A Socio Holdings Co., Ltd. (000640.KS)
- Previous Close
114,000.00 - Open
112,600.00 - Bid --
- Ask --
- Day's Range
112,300.00 - 114,200.00 - 52 Week Range
76,800.00 - 121,400.00 - Volume
3,158 - Avg. Volume
8,273 - Market Cap (intraday)
701.956B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield 2,200.00 (1.96%)
- Ex-Dividend Date Dec 27, 2023
- 1y Target Est
143,333.00
Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It develops DA-1241 for the treatment of type 2 diabetes and non-alcoholic steatohepatitis; DA-1726, an oxyntomodulin analogue to treat obesity; DA-1229, a dipeptidyl peptidase-4 inhibitor class treatment for type 2 diabetes; DA-8010, a muscarinic M3 receptor antagonist for the treatment of overactive bladder; DMB-3115, a biosimilar of Stelara and an inflammatory disease treatment; DA-3880 to treat anemia; STP0404, an HIV-1 treatment drug; and STP1002, an anti-cancer drug. The company also provides healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and derma business areas; CDMO services; imaging equipment and ENT workstation products; mineral water under the Cheonnyeonsu brand name; and IT and construction services. In addition, it produces glass bottles, PET, and corrugated cardboard boxes; engages in the foundry equipment, logistics, and food and beverage businesses. The company was founded in 1932 and is headquartered in Seoul, South Korea.
www.donga.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000640.KS
Performance Overview: 000640.KS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000640.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000640.KS
Valuation Measures
Market Cap
701.96B
Enterprise Value
1.23T
Trailing P/E
12.11
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.62
Price/Book (mrq)
0.69
Enterprise Value/Revenue
1.09
Enterprise Value/EBITDA
7.58
Financial Highlights
Profitability and Income Statement
Profit Margin
5.12%
Return on Assets (ttm)
2.60%
Return on Equity (ttm)
5.51%
Revenue (ttm)
1.13T
Net Income Avi to Common (ttm)
57.99B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
160.49B
Total Debt/Equity (mrq)
67.35%
Levered Free Cash Flow (ttm)
-19.3B
Research Analysis: 000640.KS
Company Insights: 000640.KS
000640.KS does not have Company Insights